Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10-8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10-8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10-8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific associat

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Plasmas Froids : Systèmes d'analyse, Modélisation et Rayonnement

I - Physique et applications atmosphériques des filaments de plasma générés par des impulsions laser ultrabrèves (Jérôme Kasparian, Jean Pierre Wolf) Spectroscopie d'émission optique sur plasma induit par laser : Principe et applications (Patrick Mauchien, Catherine Gallou, Jean Luc Lacour, Laurent Salmon) II-2. Spectroscopie de fluorescence induite par diodes laser : Application au diagnostic des plasmas (Stéphane Mazouffre) II-3. Un capteur de flux d'énergie dans les plasmas (A.-L. Thomann, N. Semmar, R. Dussart, L. Bedra, J. Mathias, Y. Tessier et S. Mazouffre) III-1. Modélisation de la photoionisation dans les plasmas d'air non-thermiques à la pression atmosphérique (Anne Bourdon, Sébastien Célestin, Julien Capeillère et Pierre Ségur) III-2. Modélisation des plasmas produits par interaction laser-matière (Tatiana E. Itina) IV-1. Propriétés et transferts radiatifs dans les plasmas (M.Y. Perrin, A. Soufiani, Ph. Riviere) IV-2. Modifications induites en surface de polymères par traitement laser (Patricia Laurens, Sophie Petit) IV-3. Lampes fluorescentes sans mercure, à la recherche de l'efficacité énergétique (Eric Robert, Sébastien Point, Sébastien Dozias, Christophe Cachoncinlle, Raymond Viladrosa et Jean Michel Pouvesle) IV-4. Sources plasmas de rayonnement X créées par laser (Fabien Dorchies) Importance du rayonnement dans les procédés thermiques industriels (Yann Cressault, Philippe Teulet, Jean-Jacques Gonzalez, Alain Gleizes) La spectroscopie optique appliquée à l'étude des disjoncteurs (Dunpin Hong, Jean-Marc Bauchire et François Gentils) Exemples de micro plasmas à haute densité : Électroérosion et ouverture de contacts électriques (Jean-Luc Dorier, Antoine Descoeudres, Christoph Hollenstein) Chauffage et génération de courant par ondes dans les tokamaks (Gérard Bonhomme